HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

Files in This Item:
RI32-6_1617-1624.pdf271.98 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/49675

Title: Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
Authors: Koike, Takao Browse this author →KAKEN DB
Harigai, Masayoshi Browse this author
Inokuma, Shigeko Browse this author
Ishiguro, Naoki Browse this author
Ryu, Junnosuke Browse this author
Takeuchi, Tsutomu Browse this author
Tanaka, Yoshiya Browse this author
Yamanaka, Hisashi Browse this author
Fujii, Koichi Browse this author
Yoshinaga, Takunari Browse this author
Freundlich, Bruce Browse this author
Suzukawa, Michio Browse this author
Keywords: Etanercept
Infliximab
Postmarketing surveillance study
Rheumatoid arthritis
TNF-α antagonists
Issue Date: Jun-2012
Publisher: Springer Berlin / Heidelberg
Journal Title: Rheumatology International
Volume: 32
Issue: 6
Start Page: 1617
End Page: 1624
Publisher DOI: 10.1007/s00296-011-1807-0
Abstract: Finding an effective treatment strategy for rheumatoid arthritis (RA) patients who have not benefited from previous tumor necrosis factor-α antagonist treatment is important for minimizing RA disease activity and improving patient outcomes. The aim of this study was to compare the safety and effectiveness of etanercept in patients with and without infliximab (IFX) treatment experience. Patients (n = 7,099) from a large postmarketing observational study of etanercept use in Japan were divided into 2 cohorts based on previous IFX use (pre-IFX and non-IFX). Baseline characteristics were assessed in each cohort. Adverse events (AEs) and European League Against Rheumatism (EULAR) responses were monitored every 4 weeks for 24 weeks. At baseline, pre-IFX patients were younger and had fewer comorbidities and a shorter RA duration than non-IFX patients. During the study, pre-IFX patients received concomitant methotrexate more often than non-IFX patients. The incidence of AEs and serious AEs were significantly lower in pre-IFX patients, as was the percentage of patients who discontinued treatment. Both cohorts had significant improvement (P < 0.001) in EULAR responses at the end of the treatment period. This study demonstrated that etanercept was effective and well tolerated in active RA patients with and without prior IFX treatment.
Type: article
URI: http://hdl.handle.net/2115/49675
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 小池 隆夫

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University